<DOC>
	<DOC>NCT02873208</DOC>
	<brief_summary>The primary objective of this study is to evaluate the long-term safety and tolerability of ALKS 3831 in subjects with schizophrenia.</brief_summary>
	<brief_title>A Phase 3, Long-term Safety and Tolerability Study of ALKS 3831 in Adults With Schizophrenia</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<criteria>Agrees to use an acceptable method of contraception for the duration of the study Subject has completed the 24week treatment period in the antecedent study, ALK3831A303, within 7 days Additional criteria may apply Subject is currently taking medications that are contraindicated with olanzapine use or exhibit druginteraction potential with olanzapine Subject has a positive test for drugs of abuse at study entry Subject is pregnant, planning to become pregnant, or breastfeeding during the study Additional criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Alkermes</keyword>
	<keyword>ALKS 3831</keyword>
	<keyword>Samidorphan</keyword>
	<keyword>Schizophrenia</keyword>
	<keyword>Safety</keyword>
</DOC>